 Immediate adverse reactions, solicited adverse reactions, unsolicited adverse events, and serious adverse events, especially intussusception, will be assessed through home visits and study clinic visits on Days 1-5, 7, 28, 56, and 84. As part of safety evaluations, a malaria test will be conducted on Days 0, 28 and 84. 